Ampio Pharmaceutical (AMPE) 8.52 $AMPE Strong On High

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ampio Pharmaceutical (AMPE) 8.52 $AMPE

Strong On High Volume: Ampio Pharmaceuticals (AMPE)
at The Street - Wed Mar 18, 9:03AM CDT
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 8.52 (+0.08)

Market Maker Surveillance Report. AMPE, EBIX, ITG, AMRN, ECOM, LOCO, Winning Stocks With Lowest Price Friction For Friday, March 13th 2015
M2 - Mon Mar 16, 6:53AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 5298 companies with "abnormal" market making, 2008 companies with positive Friction Factors and 4028 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Ampio Pharmaceuticals Inc (NYSE:AMPE), Ebix Inc (NASDAQ:EBIX), INVESTMENT TECHNOLOGY GROUP (NYSE:ITG), Amarin Corp PLC (NASDAQ:AMRN), (NYSE:ECOM), (NASDAQ:LOCO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ITG: 28.25 (+0.10), ECOM: 11.38 (-0.06), AMRN: 2.52 (-0.03), LOCO: 27.00 (+1.11), EBIX: 30.19 (-1.06), AMPE: 8.52 (+0.08)

Regulators Want Drug Companies to Be Honest About FDA
at The Street - Wed Mar 04, 12:08PM CST
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
HEB: 0.22 (-0.01), AVEO: 1.35 (-0.16), AMPE: 8.52 (+0.08), SNY: 50.64 (+1.17)

Premarket Gainers / Losers as of 9:20 am
Seeking Alpha - at Seeking Alpha - Wed Feb 25, 8:24AM CST

CBI: 45.29 (+0.86), SSH: 4.00 (-0.08), CRIS: 2.73 (-0.13), PERI: 3.30 (+0.06), PBR.A: 5.67 (+0.28), RUBI: 18.18 (-0.21), BNFT: 39.22 (+0.92), BIOC: 2.45 (-0.12), AMPE: 8.52 (+0.08), NBG: 1.34 (+0.14), WGBS: 4.17 (+0.06), HPQ: 33.28 (+0.44), WBAI: 11.06 (+1.08), PBR: 5.59 (+0.33), SMSI: 1.32 (+0.03), LC: 20.09 (+0.17), CLRX: 1.07 (-0.05), CHK: 13.61 (+0.11), BSFT: 35.20 (+0.38), SFXE: 4.30 (+0.14), ATRS: 2.67 (-0.02), CHS: 18.24 (+0.11), CAPN: 5.37 (-0.33), SLCA: 31.49 (+1.66)

Ampio Too Busy to Tell Investors Results of Eye Drug Study
at The Street - Wed Feb 25, 6:55AM CST
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
AMPE: 8.52 (+0.08)

Technical Report on Pharma Stocks -- Novo Nordisk, Theravance, XenoPort, Cempra, and Ampio Pharma
PR Newswire - Wed Feb 18, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NVO: 49.53 (+1.33), THRXV: 28.00 (+7.07), AMPE: 8.52 (+0.08), CEMP: 39.77 (-1.15), THRX: 17.03 (-0.94), XNPT: 8.38 (-0.08)

Drug Delivery Partnering Terms and Agreements 2015
M2 - Mon Feb 16, 10:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpgmrs/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The drug delivery technology includes the following sub-technology areas: - Bioavailability - Implanatable - Oral delivery - Rapid release - Delayed release - Parenteral - Infusion - Injectable - Pro-drug - Targeted - Tropical - Transdermal - Buccal - Inhaled - Nasal - Ocular - Rectal - Sublingual - Urogenital Companies Mentioned: 30 of the 350 Companies that Feature in this Extensive Report - 3M - 3M Drug Delivery Systems - AAIPharma Services - Abbott - Accredo Health Group - Acelrx Pharmaceuticals - Acorda Therapeutics - Actavis - Actelion - Actient Pharmaceuticals - Adeona Pharmaceuticals - Adolor - Alchemia - Aldexa Therapeutics - Alexza Pharmaceuticals - Alfacell - Alimera Sciences - Alkermes - Allergan - Allos Therapeutics - Amag Pharmaceuticals - AMAG Pharmaceuticals - Amarillo Biosciences - Amarin - Amicus Therapeutics - Ampio Pharmaceuticals - Amylin Pharmaceuticals - Anesiva - Angiotech Pharmaceuticals - AP Pharma For more information visit http://www.researchandmarkets.com/research/rp...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AMPE: 8.52 (+0.08), ACOR: 34.74 (-0.39), ALKS: 67.20 (-0.86), ALXA: 2.13 (-0.04), AGN: 240.22 (+2.88), ALDX: 10.80 (+0.20), ALIM: 5.12 (+0.08), AMAG: 58.20 (-0.04), FOLD: 11.61 (-0.85)

Ampio Pharmaceuticals (AMPE) Is Weak On High Volume Today
at The Street - Fri Feb 13, 9:04AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate
AMPE: 8.52 (+0.08)

Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST

MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), CBYL: (), ANIK: 40.84 (-0.63)

Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST

MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), CBYL: (), ANIK: 40.84 (-0.63)

Sell Your Ampio Pharmaceuticals Shares Now: AMPE Is Setting Up For A Secondary
Alpha Exposure - Seeking Alpha - Tue Jan 27, 12:52PM CST
We believe Ampio Pharmaceuticals (NYSEMKT: AMPE ) is a stock promotion that is run by management with an alleged history of fraud and is aggressively promoting itself in preparation for a secondary. AMPE is quickly running out of cash and needs to...
UNXL: 6.55 (-0.33), AMPE: 8.52 (+0.08)

Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST

MNK: 132.47 (+1.26), FLXN: 28.32 (-0.74), XENE: 18.58 (-0.11), HZNP: 22.77 (-0.30), AMPE: 8.52 (+0.08), ANIK: 40.84 (-0.63), CBYL: ()

Ampio Pharmaceuticals (AMPE) Strong On High Relative Volume Today
at The Street - Tue Jan 27, 9:02AM CST
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 8.52 (+0.08)

Luoxis Establishes Initial European Distribution Network for RedoxSYS(TM) Diagnostic System
PR Newswire - Thu Jan 22, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced it has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS(TM) Diagnostic System to prominent academic and pharma-based research centers within their respective territories. RedoxSYS is a first-in-class diagnostic platform and robust research tool capable of measuring oxidation-reduction potential (ORP) in the body in response to injury, illness, or stress.
AMPE: 8.52 (+0.08)

Ampio Pharmaceuticals (AMPE) in Focus: Stock Surges 14.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 15, 8:39AM CST
Ampio Pharmaceuticals, Inc. (AMPE) was a big mover last session, as the company saw its shares rise over 14% on the day.
AMPE: 8.52 (+0.08), IG: 9.32 (+0.65)

Ampio Pharma up after Vyrix presentation
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 2:45PM CST

AMPE: 8.52 (+0.08)

Vyrix Pharmaceuticals to Present at Biotech Showcase(TM) 2015
PR Newswire - Thu Jan 08, 6:57AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, Inc. is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 8.52 (+0.08)

Luoxis to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 7:00AM CST
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
AMPE: 8.52 (+0.08)

Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014
PR Newswire - Thu Dec 04, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the 25th Annual Oppenheimer Healthcare Conference on Thursday, December 11th, 2014. The presentation is scheduled for 11:30 AM Eastern Time at the Crown Plaza Hotel in New York City.
AMPE: 8.52 (+0.08)

Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (STRUT) Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial
PR Newswire - Mon Dec 01, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT open label portion (n=7) of the multiple injection study at week 20 of the study.
AMPE: 8.52 (+0.08)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 180

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 104

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 111

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 132

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 117

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 133

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading

Top 5 Most Recently Viewed Articles

Unlocking the Future of Health with ELMCRx and ETS Partnership

Updated Category News Views 154

ELMCRx Solutions and ETS Partnership ELMCRx Solutions is forging new paths within the healthcare landscape through its strategic alliance with Emerging Therapy Solutions (ETS). This collaboration is tailored to address the innovative and costly challenges posed by cell and gene therapies (CGT). ELMCRx stands out as a pharmacy benefit manager (PBM) dedicated to providing...

Continue Reading
International Symposium on Microbes and Cancer Research

Updated Category News Views 203

International Symposium on Microbes and Cancer Research Set for March 2-3, the upcoming conference promises to bring together globally recognized experts from various fields related to cancer science. The event, hosted by Tampa General Hospital (TGH) Cancer Institute and the USF Health Morsani College of Medicine, will highlight critical intersections between microbes,...

Continue Reading
Freddie Mac Welcomes Matthew Abrusci as New General Counsel

Updated Category News Views 314

Freddie Mac Names Matthew Abrusci as General Counsel MCLEAN, Va. — Freddie Mac (OTCQB: FMCC) proudly announces the appointment of Matthew D. Abrusci as its new Executive Vice President, General Counsel, and Corporate Secretary. With his extensive experience in financial services, Abrusci is set to make significant contributions to the organization. Matthew Abrusci's...

Continue Reading
Energizer Holdings Declares Increased Dividend for Shareholders

Updated Category News Views 188

Energizer Holdings Announces Dividend for Shareholders Energizer Holdings, Inc. (NYSE: ENR) recently declared a quarterly dividend, highlighting the company’s ongoing dedication to its investors. The Board of Directors determined that each share of common stock will receive a dividend of $0.30, reflecting the organization's solid performance and commitment to returning...

Continue Reading
Tevogen Bio: Pioneering Cost-Effective Innovations in Biopharma

Updated Category News Views 199

Tevogen Bio's Innovative Approach to Healthcare As the biopharma sector navigates an increasingly competitive landscape, Tevogen Bio Holdings Inc. (NASDAQ: TVGN) stands out for its commitment to delivering groundbreaking medical solutions while maintaining affordability. This dedication is crucial as international competitors, particularly from China, develop drugs more...

Continue Reading